18F-FDG PET/CT显像应用于恶性淋巴瘤的临床价值

摘要

Objective To evaluate 18F-fluorodeoxyglucose PET/CT imaging for the diagnosis,staging and treatment evaluation of lymphoma. Methods Before definite therapy,59 patients underwent PET/CT imaging and were diagnosed for lymphoma.The results of PET/CT imaging were compared before and after treatment in 17 patients. Results 54 patients with lymphoma were determined by pathology(44 NHL patients and 10 HL patients).Without any treatment,the sensitivity, specificity and accuracy of PET/CT in identifying lymphoma was 100%, 91.5%, 91.5% respectively,and it led to change 20.4% in clinical staging and 9.3% in management. 18F-FDG PET/CT and BMB produced equivalent results in patients.After 2~4 courses of treatment, 6 of the 17 cases show the tumors were mildly suppressed,the other 11 cases had the residual sites or new sites. Conclusion 18F-FDG PET/CT imaging plays an important role in diagnosis,staging and treatment evaluation.It is useful for differentiating active tumors from fibrosis and necrosis after treatment.%目的 探讨18F-FDG PET/CT显像对恶性淋巴瘤的临床分期和疗效评价方面的临床价值.方法 回顾性分析59例PET/CT显像结果诊断为恶性淋巴瘤的初诊患者,并对17例治疗前后的PET/CT显像结果进行对照分析.结果 病理证实54例为恶性淋巴瘤(非霍奇金淋巴瘤44例,霍奇金淋巴瘤10例),PET/CT显像的敏感性、特异性、准确性分别为100%、91.5%、91.5%.其中11例(20.4%)的临床分期得到上调,并改变了5例(9.3%)的治疗方案. 18F-FDG PET/CT显像与骨髓穿刺结果基本一致.对照研究中17例中的6例示病灶处于抑制状态,11例示肿瘤残存或新发阳性病灶.结论 18F-FDG PET/CT显像在恶性淋巴瘤的临床分期及疗效评价方面具有重要的临床意义,有助于残余病灶性质的鉴别.